论文部分内容阅读
目的:探讨阿托伐他汀强化降脂对急性冠脉综合征(ACS)患者血清高敏C-反应蛋白(hs-CRP)的影响及其对ACS炎症抑制和斑块稳定的作用。方法:80例ACS患者随机分为两组各40例,常规治疗组予常规药物治疗,但不用降脂药物;阿托伐他汀组在常规治疗的基础上予阿托伐他汀40mg/d,口服疗程2个月。治疗后7天及30天抽取静脉血检测血清hs-CRP水平。结果:治疗后7天,阿托伐他汀组血清hs-CRP水平较治疗前明显降低(P<0.05),而常规治疗组无明显变化;治疗后30天,常规治疗组血清hs-CRP水平降至正常,而阿托伐他汀组血清hs-CRP水平降低程度较常规治疗组更为明显(P<0.05)。结论:阿托伐他汀能降低ACS患者的血清炎症因子,具有抑制炎症和稳定斑块作用。
Objective: To investigate the effect of atorvastatin on serum hs-CRP in patients with acute coronary syndrome (ACS) and its effect on inflammation inhibition and plaque stability. Methods: Eighty ACS patients were randomly divided into two groups of 40 cases. The conventional treatment group was given conventional drug therapy without lipid-lowering drugs. The atorvastatin group was treated with atorvastatin 40 mg / d on the basis of routine treatment. Course of 2 months. Serum hs-CRP levels were measured at 7 and 30 days after treatment. Results: At 7 days after treatment, serum hs-CRP level in atorvastatin group was significantly lower than that before treatment (P <0.05), while there was no significant difference in routine treatment group. At 30 days after treatment, serum hs-CRP level To normal, while the level of serum hs-CRP in atorvastatin group decreased more significantly than the conventional treatment group (P <0.05). Conclusion: Atorvastatin can reduce serum inflammatory cytokines in ACS patients and inhibit the inflammation and stabilize the plaque.